Pharma Journalist -

Pelthos Therapeutics Inc. has acquired the U.S. commercialization rights to Xepi® (ozenoxacin) Cream, 1%, from Biofrontera Inc. and Ferrer Internacional S.A., expanding its dermatology…
Read More...

Alvotech and Advanz Pharma have announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisations for all four presentations of…
Read More...

Abzena, a leading end-to-end contract development and manufacturing organization (CDMO) for complex biologics and bioconjugates, has announced a strategic partnership with Mabqi, a…
Read More...

Novo Nordisk unveiled new findings from its OASIS 4 Phase 3 trial at ObesityWeek® 2025 in Atlanta, reinforcing the potential of oral semaglutide 25 mg as a treatment option for adults…
Read More...

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) as a single-agent therapy for adults…
Read More...

Jupiter Neurosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2a clinical trial…
Read More...

Leukogene Therapeutics Inc. (LTI), a biopharmaceutical company focused on developing next-generation immunotherapies for blood and solid cancers, announced that the U.S. Food and Drug…
Read More...

Pacira BioSciences, Inc. has announced an exclusive worldwide license and collaboration agreement with AmacaThera to develop and commercialize AMT-143, a novel long-acting formulation…
Read More...

Merck, known as MSD outside the U.S. and Canada, has entered into a $700 million funding agreement with Blackstone Life Sciences to support the development of sacituzumab tirumotecan…
Read More...

Avant Technologies Inc., a Nevada-based corporation, and Singapore-based biotechnology firm SGAustria Pte. Ltd. have announced a Joint Venture and License Agreement to pioneer…
Read More...